Fig. 7

Cellular roles of CDKN2C in HR + HER2- breast cancer cells. (A) The overexpression efficiency of CDKN2C in HR + HER2- breast cancer cells was assessed by Western blotting. NS: P > 0.05, ***: P ≤ 0.001. (B) The proliferative capacity of control and CDKN2C-overpressed cells was examined by clone formation assay. **: P ≤ 0.01, ***: P ≤ 0.001. (C) Cell cycle analysis of control and CDKN2C-overpressed cells was examined by flow cytometry assay. (D) The expression of PCNA in control and CDKN2C-overpressed cells was examined by Western blotting.